Unalium

Quick links to important sections

Unalium

Method of action: Other Nervous System Drugs

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Unalium

Unalium is a brand name for the active pharmaceutical ingredient Flunarizine, a synthetic compound primarily known for its role as a selective calcium entry blocker. It is a prescription-only medicine designed to be taken orally for stabilizing chronic physiological processes.

What Type of Medicine is Unalium (Flunarizine)?

Flunarizine belongs to the pharmacological class of calcium entry blockers, which function by regulating the movement of calcium ions across cell membranes. The chemical structure classifies this agent as a diphenylmethylpiperazine derivative, often administered in its stable salt form as Flunarizine dihydrochloride. As a selective agent, it has a preferential affinity for specific calcium channels, which minimizes direct cardiovascular impact while possessing ancillary antihistamine (H1) properties. It is utilized in the management of chronic neurological stability.

Composition, Form, and General Purpose

Unalium is a single-ingredient product, available for oral administration in standardized solid dosage forms, specifically the tablet or capsule. This composition allows for systemic delivery. The medication's general purpose is to function as a prophylactic agent, aiming to limit cellular over-excitation and provide a protective anti-vasoconstrictor effect rather than resolving acute episodes. Flunarizine is used for managing conditions associated with vascular instability, such as those that lead to recurrent vestibular issues. The medicine helps reduce the likelihood of episodes by stabilizing the circulatory system over time.

How Flunarizine Relates to Chronic Vascular Stability

The core function of Flunarizine is to foster chronic physiological stability by mitigating the impact of factors leading to vascular instability. Its action is designed to reduce the body's overall reactivity to triggers by stabilizing cell function and protecting blood vessels from unnecessary spasm. The medication is positioned for patients requiring long-term, preventative neurological support. By creating a sustained, calmer environment for neurological and circulatory processes, the therapeutic goal focuses on managing conditions linked to chronic neuronal hypersensitivity and vascular instability, thereby reducing the frequency of related episodes.

Regulatory References

  1. NIH MeSH

What side effects are possible with Unalium?

Possible Side Effects and Safety Information

The safety profile for Unalium (Flunarizine) outlines adverse reactions grouped by frequency and the body systems they affect, based strictly on official regulatory documentation.


Frequency and System-Organ Classes

The most frequently reported effects are classified as Common (affecting up to 1 in 10 patients) and are centered on the central nervous system and metabolic processes. Common effects include weight increase, increased appetite, sedation, drowsiness, fatigue, and depression. Side effects classified as Uncommon (affecting up to 1 in 100 patients) include extrapyramidal symptoms (such as tremor and slow movement), anxiety, muscle pain (myalgia), and breast pain.


Serious Reactions and Safety Constraints

The regulatory safety profile highlights the potential for two serious adverse reactions: the development of depression and extrapyramidal symptoms, which can manifest as Parkinsonism. The official documentation explicitly notes that these serious effects are often associated with long-term use.

Safety constraints and restrictions on use are specified for certain populations and pre-existing conditions. Use is typically restricted in patients with a history of depressive illness or existing Parkinson's disease or other extrapyramidal disorders. Older adults are specifically noted in the official labeling as having a greater potential risk for developing both depressive and extrapyramidal symptoms. Additionally, co-administration with alcohol or other central nervous system depressants may increase the sedative effects, and the medicine is constrained in cases of severe hepatic impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Unalium (Flunarizine) requires immediate professional medical attention. Official regulatory documentation outlines the expected and observed physiological manifestations that occur following high dose exposure, which may include documented single intakes up to 600 mg.

Overdose Manifestations Observed/Expected Symptoms
Central Nervous System (CNS) Effects Sedation, asthenia (physical weakness), confusion, and agitation.
Cardiovascular Effects Tachycardia (abnormally fast heart rate).

The appearance of these acute symptoms, particularly the severe CNS manifestations and cardiovascular signs like tachycardia, establishes the condition for seeking urgent medical assistance. This prompt action is necessitated because the regulatory prescribing information explicitly states that no specific antidote is known for Flunarizine overdosage.

Management of acute overdosage is therefore strictly symptomatic and supportive. Regulatory guidance specifies that professional procedures may involve charcoal administration or gastric lavage, if deemed appropriate by medical personnel, alongside continuous supportive measures and observation designed to stabilize the patient’s vital functions. Any known or suspected exposure exceeding the normal prescribed regimen requires immediate contact with emergency medical services for assessment and treatment.

Therapeutic Uses of Unalium

What Unalium Treats: Main Uses and Benefits

This medication is commonly used to help with symptoms related to heightened neurological activity, and may be part of symptomatic management for conditions characterized by periods of heightened symptoms.

The medication is utilized across domains where additional symptomatic support is needed. It is commonly used to help address symptom clusters that may become intense or disruptive, such as migraine, the sensation of spinning (vertigo), and chronic unsteadiness. It is relevant for managing symptoms associated with recurrent or episodic manifestations, and may provide supportive relief when symptoms interfere with routine activities.

It is also considered relevant for addressing symptoms that create noticeable physiological strain, such as occasional coldness or discomfort in the extremities. This supportive action assists with maintaining functional stability and supports general well-being during symptomatic phases.

“It may assist with managing the frequency of episodic manifestations.”

Quick Fact: Relief for Recurrent Headache

Regulatory References

  1. NIH MeSH overview

Eligibility and Restrictions for Use

Eligibility for Unalium (Flunarizine): Official Regulatory Status

Eligibility to use Unalium is strictly defined by government regulatory documents, focusing on patient population and specific health conditions. The medicine is generally established for use in adults (18 years and older) for migraine prophylaxis. Use in adolescents (12 to 18 years) is considered conditional, often reserved for cases where other preventative treatments have failed or are not tolerated.

Absolute Contraindications

Unalium is absolutely contraindicated and must not be used by patients with:

  • A known hypersensitivity to flunarizine or its components.
  • A history of depressive illness or recurrent depressive episodes.
  • Pre-existing symptoms of Parkinson's disease or other extrapyramidal disorders.

Special Populations and Restrictions

Regulatory agencies advise that the medicine is not recommended for use during pregnancy or while breastfeeding. Furthermore, use in children under 12 years is generally not recommended as the safety and efficacy are not established for standard indications. Caution is mandatory when prescribing to older adults and patients with hepatic impairment, as these groups require close monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define specific substance classes and medicines that interact with Unalium (Flunarizine), primarily through additive effects on the central nervous system (CNS) and through changes to the drug's metabolism.


Pharmacodynamic and Contraindicated Interactions

Substance Category Documented Interaction Outcome
Monoamine oxidase inhibitors (MAOIs) Contraindicated combination due to the potential for severe cardiovascular and CNS reactions.
CNS Depressants (e.g., Benzodiazepines, sedatives) Risk of enhanced sedative effects and increased drowsiness.
Alcohol Must be avoided or limited due to the risk of excessive sedation.
Cardiovascular Agents (e.g., beta-blockers) May potentiate hypotensive effects (blood pressure lowering).

Pharmacokinetic and Exposure Interactions

Substance Interaction Type and Outcome
Enzyme-Inducing Anticonvulsants (e.g., Carbamazepine, Phenytoin) Increased metabolism of Flunarizine, which may lead to reduced plasma concentrations.
Topiramate Documented to cause an increase in the total systemic exposure (AUC) of Flunarizine.
High-fat meals Administration with food is documented to increase total systemic exposure (AUC) by 20%.
Oral Hormonal Contraceptives Flunarizine is documented to potentially reduce contraceptive efficacy.

All interaction statements are based strictly on official product information and regulatory warnings regarding concomitant use.

Mechanism of Action

Unalium's action involves the effect on neuronal and vascular activity via specific mechanistic domains, contributing to changes in cellular excitability and vascular tone.


Selective Calcium Channel Blockade

This domain covers Unalium's core function: inhibiting the influx of calcium ions (Ca^2+) through voltage-dependent channels, specifically T- and L-type channels, in neuronal and vascular smooth muscle cells. This mechanism engages processes that regulate overactive signaling and leads to the stabilization of cell membranes, altering neuronal and smooth muscle cell activity.


Auxiliary Receptor Antagonism

Beyond calcium modulation, Unalium engages mechanisms that affect other signaling pathways, including moderate antagonism at the Histamine H1 and Dopamine D2 receptors. This activity influences systems where these specific transmitters or mediators dominate, resulting in reduced activity of targeted mediator pathways and facilitating the modulation of activity within those pathways.


Neuroprotection and Hemorheological Effects

This mechanistic domain involves the drug’s potential to limit cell damage often associated with calcium overload and its ability to influence blood viscosity and circulation. By modifying early molecular steps that shape systemic physiological outcomes, Unalium exhibits an influence on cellular calcium management and microcirculatory hemorheological properties.

Dosage and Administration Information

Unalium (Flunarizine) is an oral medication, typically available in tablet or capsule form, designed for once-daily administration. The regimen is structured into defined initial and maintenance phases, with specific parameters for dosage, timing, and duration.

Administration and Dosage Regimen

The medicine is uniformly administered via the oral route. The daily dose is taken at night.

Age Group Initial Daily Dose (Once at Night) Constraint
Adults (18–64 yrs) 10 mg Do not exceed this dose daily
Older Adults (65 yrs and older) 5 mg Lower starting dose is utilized

Initial treatment is continued for an assessment period of 2 months. If there is no significant improvement during this time, administration is typically discontinued. Since the medicine may take 5 to 6 weeks to reach steady-state concentration, regular, continuous intake is required during this phase.

Maintenance and Duration

For those who respond to the treatment, a cyclic maintenance schedule is utilized. This involves continuing the standard daily dose but incorporating an interruption of two successive drug-free days every week. Even if the treatment remains successful and well-tolerated, continuous prophylactic use is interrupted after 6 months, and the treatment is only re-initiated if there is a relapse. If a daily dose is missed, the usual practice is to skip the missed dose if it is close to the time for the next scheduled dose and continue the regular dosing pattern.

Recent Clinical Evidence

Research evidence / Overview of Studies for Unalium

The following summary provides an overview of the clinical research conducted on Unalium (Flunarizine), focusing strictly on the types of studies, the outcomes they measured, and the limitations noted in the official and peer-reviewed scientific literature. This information is descriptive and does not constitute medical advice or recommendations.


Evidence for Use in Migraine Prophylaxis

Research exploring the use of Unalium in contexts related to recurrent headaches has been primarily conducted using Randomized Controlled Trials (RCTs) and subsequently summarized in systematic reviews. Research focused on changes in the frequency of monthly migraine attacks and outcomes related to physical discomfort, such as the reported intensity and duration of the episodes.

Findings derived from systematic reviews and meta-analyses of these trials describe patterns of change in measured attack frequency over short-term periods (typically up to four to six months). Research has also explored the compound in trials where other treatments were used as active comparators, and some studies collected data on outcomes reflecting daily functioning or activity level.


Evidence for Vertigo and Vestibular Disorders

For conditions associated with acute or disruptive episodes like recurrent vertigo or dizziness, Unalium was studied for its use in exploring the frequency of attacks. Available evidence includes both RCTs and smaller, controlled trials that research examined how symptoms evolved in the observed populations. Researchers focused on outcomes related to systemic or functional imbalance and patient-reported outcomes describing perceived discomfort.

In some trials where other active compounds were used, research has noted that findings were mixed or inconsistent. Data show patterns related to changes in reported symptoms and in the measured frequency of episodes in studies involving patients with recurrent paroxysmal vertigo, including those with vestibular migraine.


Key Limitations and Areas of Research Uncertainty

The research record presents several limitations. Many of the core efficacy studies are older, meaning they were conducted before modern clinical trial design and reporting standards were fully established. Also, follow-up durations were limited in many cases, meaning long-term effects are not fully established.

Dedicated research specifically focused on children and adolescents often involves small-scale studies, and data for certain groups remain insufficient, meaning that subgroup findings are uncertain.

Research provides context but not individual predictions. Findings describe group patterns, and the evidence highlights what is known, as well as what is still uncertain, especially regarding long-term functional changes and data for certain patient groups.

Key Studies & References

  1. Assessment of Flunarizine in Vestibular Disorders and Vertigo: A Systematic Review of Controlled Trials
  2. Flunarizine: NIH MeSH Classification and Pharmacological Studies Overview

Frequently Asked Questions (FAQ)

Common questions about Unalium (FAQ)

Q: How quickly does Unalium typically start to work?

A: Official pharmacokinetic studies indicate that the drug’s concentration in the body reaches a steady, consistent level after approximately five to six weeks of consistent daily intake. Because the medication is used for chronic prevention, the full therapeutic benefit may require several months of consistent intake before being assessed by a healthcare provider.

Q: What is the difference between Unalium and other similar medications?

A: Unalium's active ingredient is classified as a selective calcium entry blocker. It also possesses ancillary activity as a moderate antagonist, which means it blocks, to a lesser extent, certain Histamine H1 and Dopamine D2 receptors.

Q: Is it normal to feel slightly dizzy when first starting Unalium?

A: Official regulatory documents list both drowsiness (somnolence) and dizziness as commonly reported side effects of the medication. The emergence of these effects is typically monitored during the initial treatment period.

Q: Does Unalium interact with common over-the-counter pain relievers?

A: Official information documents specific interactions with some over-the-counter drugs. For example, the metabolism of Unalium may be altered by medicines like acetaminophen, and co-administration with acetylsalicylic acid may be associated with an increased risk of certain metabolic changes.

Q: Can teenagers or children use Unalium?

A: Official regulatory documents state that use of the medication is generally not recommended for children under 18 years of age. This recommendation is based on the general lack of established safety and efficacy data for the standard approved indications in this age group.

Q: Do patients typically need to take Unalium with food or on an empty stomach?

A: Official pharmacokinetic findings show that taking the medication with a high-fat meal can increase the total amount of the drug the body absorbs. However, the medication can generally be taken with or without food.

Q: How long after stopping Unalium will it be completely out of my system?

A: The drug has a prolonged presence in the body. Its elimination half-life—the time it takes for the amount of drug to be reduced by half—is lengthy after chronic use, averaging between approximately 4 and 19 days.

Q: Can Unalium affect my sleep patterns?

A: Official product information lists sleep disturbance as one of the reported adverse effects of the medication.

Q: What are the signs of a serious or rare side effect from Unalium?

A: Serious adverse effects are documented in official safety information. These signs may be related to extrapyramidal symptoms or new onset of depression, and patients are advised to seek medical attention if any unusual movements or mood changes occur.

Q: Are there different strengths or formulations of Unalium?

A: The medication is available for oral administration in solid dosage forms, specifically tablets and capsules. These are documented in various strengths, such as 5 mg, with 10 mg doses also referenced in the official clinical dosing regimens.

Q: Where can I find the official prescribing information for Unalium?

A: The official prescribing and safety information can be found in government-run regulatory documents, such as the Summary of Product Characteristics (SmPC) or the Health Canada Monograph, which are published by the relevant governing health authorities.

Q: Is Unalium available as a generic medicine?

A: The active pharmaceutical ingredient is flunarizine, which is the non-proprietary name used consistently across regulatory documentation. This naming convention is the basis for potential generic products.

Q: What should I do if I feel like Unalium is not working?

A: Official guidance defines an initial treatment phase, usually lasting two months, after which a healthcare provider will assess if the medication should be continued or discontinued based on the patient's progress and response.

Q: Is it common for doctors to adjust the dose of Unalium over time?

A: Yes, the official regulatory regimen is structured to define both an initial daily dosing phase and a subsequent cyclic maintenance schedule. This naturally involves a change in the administration pattern over time.

Q: Why is it important to tell my doctor about all the medicines I take with Unalium?

A: Disclosure is important because official documents list numerous documented interactions. These include additive sedative effects with certain Central Nervous System (CNS) depressants and pharmacokinetic changes when taken with other medicines that alter the drug’s metabolism.

Q: Can Unalium affect my ability to drive or operate machinery?

A: Yes. Because the medication may cause drowsiness, official regulatory labeling explicitly advises patients to avoid driving or operating heavy machinery until they are certain they are not affected by this side effect.

Q: What should I do if I accidentally take two doses of Unalium at once?

A: In the event of accidental ingestion of a large dose, official regulatory guidance advises seeking medical attention immediately, as monitoring of vital signs, such as an electrocardiogram, may be suggested.

Q: Does Unalium cause skin sensitivity to the sun?

A: Official product information notes that sensitivity to light (photosensitivity) has been observed. This is typically mentioned as a potential component of rare allergic reactions.

Q: Can Unalium be used by people with kidney impairment?

A: The drug is primarily metabolized in the liver, and only a minimal amount is excreted through the kidneys. Because of the route of elimination, regulatory documents generally do not provide specific dosage adjustments for kidney impairment.

Q: Are there any specific foods or drinks that should be avoided while taking Unalium?

A: The regulatory label advises that alcohol must be avoided or limited due to the risk of excessive sedation. High-fat meals are also documented to increase the amount of drug the body absorbs.

Q: Does Unalium interact with herbal supplements like St. John's Wort?

A: Official information documents pharmacokinetic interactions with enzyme-inducing substances, a category that can include certain herbal supplements. These interactions may lead to reduced blood levels of Unalium.

Q: Are the side effects of Unalium permanent?

A: Regulatory safety documents note that symptoms of serious adverse effects, such as movement disorders, generally show improvement after the medication is discontinued.

Q: Why do some people need to have blood tests while taking Unalium?

A: Monitoring of liver function may be considered for certain patients, particularly those who are taking this drug in combination with multiple other medications.

How should Unalium be stored and disposed of?

Storage and Disposal Requirements

Scope Element Official Regulatory Requirement
Labeled Storage Temperature: Store at a temperature not exceeding 30 C (below 30 C).
Protection Requirements: Must be stored in a dry place and protected from light.
Handling Constraints: Do not freeze. Keep away from excessive heat.
Packaging Rules: Keep the container tightly closed. Store in the original container.
Child-Safety Storage: Mandatory to keep medicine out of reach of children.
Disposal Instructions: Dispose of unused or expired product according to local regulations.
Environmental Restrictions: Do not dispose of in wastewater or household trash; return to a designated collection point.

Official regulatory documents define strict criteria for maintaining the drug's integrity and ensuring public safety. These criteria prohibit storage above the specified room temperature and require protection from moisture and light to maintain product stability. Discarding unused product must follow specialized pharmaceutical waste procedures, explicitly forbidding disposal into sinks, toilets, or regular household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Unalium found in:

A-Z Index: